Investigating the Interactions of AZD0530 With Alcohol in Social Drinkers
Status:
Completed
Trial end date:
2016-03-23
Target enrollment:
Participant gender:
Summary
The purpose of this alcohol-interaction pilot study is to provide information on the effect
of AZD0530 (Saracatinib) on the pharmacokinetics of alcohol and on alcohol responses,
including stimulation, sedation, intoxication, body sway and physiological responses. The
investigators propose to test the effects of a single dose of AZD0530 (125 mg) on alcohol
related responses. This is a within subjects open label study in which the investigators plan
to run 8 subjects to obtain 5 completers.
Phase:
Phase 1
Details
Lead Sponsor:
Yale University
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)